MedTrace Logo

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

NCT04908215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-07-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (EB).

Conditions

  • Epidermolysis Bullosa Simplex
  • Epidermolysis Bullosa, Junctional
  • Epidermolysis Bullosa Dystrophica
  • Kindler Syndrome

Interventions

DRUG

INM-755 (cannabinol) cream

topical cream containing cannabinol for dermal application

DRUG

Vehicle Cream

topical cream base for dermal application containing no active agent

Sponsors & Collaborators

  • InMed Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Alexandra DJ Mancini, MSc · InMed Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-28
Primary Completion
2023-04-03
Completion
2023-04-19

Countries

  • France
  • Germany
  • Greece
  • Israel
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04908215 on ClinicalTrials.gov